Nexcella

Focus: Nexcella is a public biotechnology company focused on CAR-T cell therapy development, headquartered in Los Angeles. The company is in early-stage clinical development with a specialized focus on cell therapy treatments.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Nexcella

AI assessmentNot Hiring

No open roles listed right now. Follow Nexcella to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NXC-201

Dose Escalation and Safety

PHASE_1

Clinical Trials (1)

NCT04720313NXC-201 (formerly HBI0101) Multiple Myeloma

Phase 1

Help build intelligence for Nexcella

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work in cutting-edge CAR-T cell therapy, one of the most advanced immunotherapy modalities with significant clinical validation in oncology
Public company status provides equity upside and access to capital markets, offering career stability and growth potential
Specialized focus on a high-value therapeutic area with limited competition compared to large pharma

Watch Out For

Currently zero open positions and minimal hiring activity suggest limited near-term career development opportunities
Early-stage pipeline with only Phase 1/1b programs indicates 5+ years before potential revenue generation and clinical validation

Generated by Claude from Nexcella's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NXC-201 CAR-T

Light Chain (AL) Amyloidosis

PHASE_1_2

Clinical Trials (1)

NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo